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Targeting Acute Myeloid Leukemia Cells with Novel 
Photosensitive Ruthenium-Based Metal-Organic 
Compounds 
 
Daniel Fadi Azar 
 
ABSTRACT 
 
Acute myeloid leukemia (AML) is a class of hematopoietic malignancies that is 
characterized by the accumulation of abnormally differentiated myeloid cells and 
their infiltration into the bone marrow, blood and other tissues. Prognosis of 
patients diagnosed with AML remains low in all age groups, and most currently 
approved therapies against AML have serious side-effects and limited potency, 
necessitating the development of alternative, more potent approaches that could 
specifically target cancerous cells. Promising results have been reported in the field 
of Metallomics, in which various cancers have been targeted by compounds formed 
of different ligands conjugated to a metal core, one of which being ruthenium (Ru). 
Furthermore, some of these Ru complexes have been recognized for their 
photochemical potential. In this study, we sought to investigate the effects of bis-
bidentate (precursor) and tris-bidentate (final) Ru(II) metal complexes, in which the 
ligands are phenanthroline- or bipyridine-derivatives, on a panel of human AML cell 
lines. We first established a structure-activity relationship of the precursors and 
their corresponding free ligands. Of the four different precursors tested {Ru-I: 
[Ru(II)(1,10-phenanthroline)2Cl2]; Ru-II: [Ru(II)(4,7-diphenyl-1,10-
phenanthroline)2Cl2]; Ru-III: [Ru(II)(4,7-diphenyl-1,10-phenanthroline-
disulfonate)2Na2]2+ and Ru-IV: [Ru(II)(2,2'-bipyridine)2Cl2]}, significant activity on 
seven out of nine cell lines, was detected only with Ru-II (IC50 values in the low µM 
range). Of the four free ligands tested (L-I, L-II, L-III and L-IV corresponding to Ru-I, 
Ru-II, Ru-III and Ru-IV, respectively), significant cytotoxic activity was detected in 
eight out of nine cell lines, only with L-I and L-II, (IC50 values in the low µM range for 
L-I and reaching the nM range for L-II). The activity of the free ligands L-I and L-II 
was at least one order of magnitude higher than that of the corresponding Ru(II) 
precursors. The activity of the metal complexes correlated with the structure of the 
ligands with modifications of phenanthroline (L-I) that make it more hydrophobic 
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strongly increasing the activity of the free ligand itself (L-II), as well as that of the 
corresponding metal complex (Ru-II). The incorporation of a negatively-charged 
group (sulfonate) even to the more hydrophobic 4,7-diphenyl-1,10-phenanthroline, 
abolishes any activity in both the free ligand (L-III) and metal complex (Ru-III), 
suggesting that DNA intercalation is a possible mechanism of action of these 
compounds. No activity was detected with the ligand-free Ru(II) metal control, 
indicating that the activity of these Ru(II) metal complexes is not due to the metal 
center alone, but to the metal coordinated to ligand. The cytotoxic effect of L-II was 
shown to occur at earlier time points than that of Ru-II, although maximum effect 
for both was reached at 72h, possibly indicating a simpler mechanism of cytotoxicity 
in the ligand. Flow cytometric analysis of the uptake of Ru-II showed early uptake (< 
1h post treatment), cell cycle analysis has shown G0-G1 cell cycle arrest at the 6h 
time-point with both L-II and Ru-II, an effect which was still observed with L-II at 
24h, whereas a higher proportion of cell death was observed with Ru-II at 24h. 
Furthermore, we have attempted to examine the photochemical potential of our 
metal-organic compound model by combining L-II and L-III in the same metal 
complex, thus generating four final complexes with differing net charges (from +2 to 
-4), and examining their activities on a panel of AML cell lines with or without 
exposure to blue light. Of the four final complexes Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-
III3, only Ru-II3 and Ru-II2-III have shown significant activity against all tested cell 
lines in the dark, whereas photo-activation against ML2 has shown a marked 
increase of potency of all four complexes, even those shown to be biologically inert 
in the dark, reaching IC50 values in the nM range. The observed potentiation by light 
was of one order of magnitude for the compounds already showing potency in the 
dark, while reaching at least two orders of magnitude for those inactive in the dark. 
We hypothesize that the increased potency observed with all four complexes upon 
exposure to light might be due to a different mechanism, namely the release of 
Reactive Oxygen Species (ROS), thus affecting the cellular metabolism and viability 
through DNA damage, lipid peroxidation, amino-acid oxidation and oxidation of 
enzyme co-factors. In this study, we aim to establish a ruthenium-based model for 
effectively targeting AML, with the goal of later developing approaches to 
selectively target AML with complexes based on this model. We are still 
investigating the role of other ligands when conjugated to a ruthenium core, as well 
as characterizing the cellular mechanisms underlying the activity of these 
compounds. 
 
Keywords: Acute Myeloid Leukemia (AML), Ruthenium, Metallomics, Metal-Organic, 
Photochemistry. 
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CHAPTER ONE 
Introduction 
 
1.1 Hematopoiesis and Hematological Disorders 
Hematopoietic cell lineages arise from the differentiation of hematopoietic 
stem cells (HSCs) that are produced and reside in the bone marrow (BM). HSCs are 
multipotent and self-renewing tissue-specific stem cells responsible for life-long 
hematopoiesis initiation and maintenance, and the differentiation of cells in all 
blood lineages (Kondo, Wagers, Manz, Prohaska, & al, 2003). HSCs comprise only 
0.01-0.2% of human BM mononuclear cells (Oguro, Ding, & Morrison, 2013). 
Lineages are distinguished as myeloid and lymphoid, whereby the myeloid lineage 
gives rise to granulocytes, erythrocytes, thrombocytes, macrophages and mast cells, 
whereas the lymphoid lineage gives rise to B cells, T cells, natural killer (NK) cells 
and plasma cells (Figure 1) (Ramdass, Chowdhary & Koka, 2013). 
 
Figure 1: Hematopoietic and stromal cell differentiation 
© 2001 Terese Winslow (assisted by Lydia Kibiuk); retrieved from “2. Bone Marrow (Hematopoietic) Stem Cells 
[Stem Cell Information],” n.d. 
HSCs are the initiators of the hematopoietic hierarchy and divide infrequently, 
thus generating further progenitor cells that are either multipotent (transient-
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amplifying multipotent progenitors [MPPs]) or lineage-restricted progenitors 
(common lymphoid or myeloid progenitors [CLPs, CMPs]; megakaryocyte-
erythrocyte progenitors [MEPs] and granulocyte-macrophage progenitors [GMPs]) 
(Figure 2) (Riether, Schürch, & Ochsenbein, 2014). This infrequent division of HSCs is 
termed quiescence or dormancy, and ensures their genetic stability (Trumpp, 
Essers, & Wilson, 2010). Hematopoietic homeostasis is the mechanism through 
which the numbers of hematopoietic cells are regulated in the body. It involves the 
process of self-renewal of the HSCs, which is defined as an asymmetrical cell 
division in which at least one of the daughter cells retains the pluripotency and the 
regenerative potential of the mother cell (Trumpp et al., 2010). The “niche”, or the 
environment necessary for the production of HSCs in the BM, is composed of a 
subpopulation of osteoblasts and endothelial cells, as well as extrinsic and intrinsic 
regulators such as transcription factors, signal transducers, epigenetic regulators 
and anti-apoptotic proteins implicated in the HSC regenerability and cell fate 
decisions (Ramdass et al., 2013). 
As opposed to the elimination of differentiated hematopoietic cells after 
exerting their actions, HSCs are preserved for long periods of time, allowing for the 
stacking of genetic insults and malignant transformations. Such flaws in self-renewal 
and the potential to differentiate may lead to hematopoietic insufficiency and 
carcinogenesis. One such example is the arising of leukemic stem cells (LSCs), 
presumably from HSCs or hematopoietic progenitor cells, from which they take on 
the regulatory mechanism, while also developing ways to counter apoptosis and 
senescence (Oguro & Iwama, 2007; Visvader, 2011; Shlush et al., 2014). 
1.1.1 Leukemia and the Rise of the Cancer Stem Cell (CSC) Theory 
The concept of hierarchical emergence of cancer from disease-originating 
cancer stem cells (CSCs) was first documented in leukemia by Lapidot et al. (1994), 
and has led to extensive research on the topic, rendering leukemia a paradigmatic 
disease of CSCs, and leading the way for the current good characterization of LSCs in 
chronic myeloid leukemia (CML) and some forms of acute myeloid leukemia (AML) 
(Schürch et al., 2013). The CSC theory has now become widely acknowledged and 
was extended to several solid tumors (Huntly & Gilliland, 2005). 
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Figure 2: The leukemic stem cell model 
HSC: Hematopoietic Stem Cells; MPP: Multipotent Progenitors; LMPP: Lymphoid-primed MPP; CLP: Common 
Lymphoid Progenitor; B: B Cell; T: T Cell; NK: Natural Killer Cell; CMP: Common Myeloid Progenitor; MEP: 
Megakaryocyte-Erythrocyte Progenitor; P: Platelet; E: Erythrocyte; GMP: Granulocyte-Macrophage Progenitor; 
M: Monocyte; G: Granulocyte; LSC: Leukemic Stem Cell. 
In normal hematopoiesis, scarcely dividing HSCs with unlimited self-renewal capacity generate transient-
amplifying MPPs that have a limited self-renewal capacity. MPPs further differentiate toward oligopotent LRPs 
such as CLPs, CMPs and GMPs that no longer possess self-renewal capacity. LRPs proliferate intensely and give 
rise to all mature blood cell types. The formation of LSC in myeloid leukemia could arise from mutations in cells in 
different stages of the hematopoietic hierarchy. (a) In chronic phase CML patients, the presence of BCR/ABL1 in 
all blood lineages suggests that the LSC is derived from an HSC or an early MPP with multi-lineage differentiation 
potential (HSC cell-of-origin). BCR/ABL1 is necessary and sufficient for the malignant phenotype, no further 
genetic lesions are required for chronic phase CML. (b) In contrast, in blast crisis CML and AML patients, LSCs 
exhibit immunophenotypes of LRPs, such as LMPPs or GMPs. This supports the concept that other more 
differentiated cells can give rise to LSCs after re-acquisition of self-renewal (progenitor cell-of-origin). (c) Further, 
the recent demonstration that some AML LSCs express low amounts of lineage markers raised the question 
whether more differentiated hematopoietic cells may also serve as cell-of-origin for LSCs. (d) In a ‘pre-leukemic' 
disease phase, genetically unstable, self-renewing LSCs clonally expand, facilitating the acquisition of further 
mutations and (e) the development of different leukemic clones. 
(From Riether, Schürch, & Ochsenbein, 2014). 
According to the CSC hypothesis, tumors are composed of a bulk of cancer 
cells markedly heterogeneous in their morphology, genetic information and 
functionality. Within this bulk resides a small subpopulation of cells with stem cell 
characteristics that disseminates the disease (Huntly & Gilliland, 2005; Reya, 
Morrison, Clarke, & Weissman, 2001). Like HSCs in hematopoiesis, LSCs are 
presumed to reside at the top of the leukemic hierarchy (Figure 2), with the 
difference that LSCs give rise to more differentiated, heterogenic leukemic blasts 
that are characterized by such features as a high proliferative capacity, an incapacity 
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for terminal differentiation as well as flawed apoptosis or senescence mechanisms, 
leading to blast accumulation and clinical disease. LSCs (and CSCs in general) 
possess stem cell features such as quiescence, high-level expression of ATP-binding 
cassette pumps and their diverse niches, rendering them especially difficult to 
eradicate (Guzman & Allan, 2014; Tabe & Konopleva, 2014). 
1.1.2 A Definition of Hematopoietic Malignancies 
Hematopoietic malignancies refer to the malignancies affecting the blood, BM 
and lymph nodes. The interconnection of these tissues through the immune system 
increases the risk of having them all affected by a disease initially arising in one of 
the three. These malignancies can affect both the myeloid as well as lymphoid 
lineages, giving rise to acute and chronic myelogenous leukemia (AML and CML), 
myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MNPs) in the 
myeloid lineage; and lymphomas, acute and chronic lymphocytic leukemias (ALL 
and CLL) and multiple myeloma in the lymphoid lineage (Ramdass et al., 2013). 
1.1.3 An Overview of Non-Leukemic Hematological Disorders and 
Malignancies 
1.1.3.1 Non-Leukemic Hematological Disorders and Malignancies 
Affecting the Lymphoid Lineage 
Lymphomas 
Lymphomas are tumors of the lymphoid lineage cells (B and T cells) that are 
predominantly observed in a nodal distribution, as opposed to leukemias, which 
form dispersed, single-celled populations (Weinberg, 2014). The two major classes 
are Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL). In adult 
lymphoblastic lymphoma (LBL), an aggressive form of NHL, no morphological 
distinctions from ALL can be observed, and segregation is made chiefly on clinical 
grounds (Portell & Sweetenham, 2012). 
Multiple Myeloma 
Multiple myeloma is the malignant counterpart of plasma cells (antibody-
producing differentiated B cells), characterized by their clonal proliferation in the 
bone marrow in a less differentiated state. It typically involves the secretion of 
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monoclonal immunoglobulins that are measurable in the urine or serum (Röllig, 
Knop, & Bornhäuser, 2015). 
1.1.3.2 Non-Leukemic Hematological Disorders and Malignancies 
Affecting the Myeloid Lineage 
Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms 
(MPNs) 
MPNs are characterized by an overproduction affecting the myeloid lineage or 
collagen in the bone marrow (Della Porta & Malcovati, 2011). Polycythemia Vera 
(PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (MF), are a group 
of non-malignant MPNs collectively described as “Philadelphia chromosome-
negative classical myeloproliferative neoplasms”. They stand in contrast to CML, 
which also falls under the general classification of MPNs by the World Health 
Organization, but is BCR-ABL1-positive (or Philadelphia chromosome-positive) and 
malignant (Choi et al., 2015; Muxí & Oliver, 2014). 
Myelodysplastic Syndrome (MDS) 
MDS is a term encompassing a group of very diverse myeloid disorders 
characterized by peripheral blood cytopenias and high propensity of exacerbation 
to acute myelogenous leukemia (AML). The incidence of MDS is higher in older 
males and in subjects previously exposed to cytotoxic therapy. Patients with MDS 
can develop severe anemia and require blood transfusions (Garcia-Manero, 2012). 
1.1.4 Leukemias 
1.1.4.1 Leukemias of the Lymphoid Lineage 
Acute Lymphoblastic Leukemia (ALL) 
ALL is a form of acute leukemia characterized by the proliferation and 
accumulation of lymphoid progenitors in the bone marrow and other tissues. Even 
though it only makes up 20% of all leukemia diagnosis in adults, it is the most 
common form of leukemia in pediatrics, and is regarded as a success story among 
pediatric malignancies, reaching cure rates of 80% or higher in this patient 
population (Jabbour, O’Brien, Konopleva, & Kantarjian, 2015). ALL stems from 
repeated genetic mutations that block precursor B and T cell differentiation and 
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promote aberrant cell proliferation and survival. Molecular subgroups of B- and T-
ALL with distinct clinical evolutions and responses to therapy are generated by 
some recurring defects such as chromosomal translocations, aneuploidies, and 
gene-specific alterations (Ramdass et al., 2013). 
Chronic Lymphocytic Leukemia (CLL) 
CLL is a malignancy of mature B lymphocytes with a well-coordinated balance 
between cell cycle-arrest and proliferation of tumor subpopulations. It is 
characterized by progressive accumulation of these malignant cells in blood, BM, 
and lymphoid tissues (Dighiero & Hamblin, 2008). A dynamic relationship with 
stromal and immune cells in the lymphatic system ensures the long-term survival 
and proliferation of CLL cells. The characteristic extreme variability of clinical 
progressions, with survival times ranging from months to decades, makes it 
necessary to stratify CLL patients according to prognostic risk (Damle et al., 1999). 
This contrasts to the relatively small number of recurrent genetic defects that are 
observed in CLL (Zent & Burack, 2014), whereas the mutational status of the B-cell 
receptor (BCR) immunoglobulin variable heavy chain (IgVH) genes is the most 
important and long-established prognostic marker (Damle et al., 1999; Döhner et 
al., 2000; Hamblin, Davis, Gardiner, Oscier, & Stevenson, 1999). 
1.1.4.2 Leukemias of the Myeloid Lineage 
Chronic Myeloid Leukemia (CML) 
CML is a clonal hematopoietic stem cell disorder with a characteristic 
translocation between the long arms of chromosomes 9 (ch9) and 22 (ch22). t(9;22) 
results in the production the fusion BCR-ABL1 gene by juxtaposition of the human 
analogue of the v-ABL oncogene from ch9 with the BCR housekeeping gene on 
ch22, thus creating the Philadelphia chromosome (Apperley, 2015). ABL1 encodes a 
non-receptor tyrosine kinase that is linked to increased proliferation, loss of stromal 
adhesion, and resistance to apoptosis (Goldman & Melo, 2001). The creation of the 
fusion gene results in the loss of control elements upstream of ABL1, resulting in a 
constitutively active protein (Bcr-Abl1) that is capable of auto-phosphorylation and 
uncontrolled signaling into downstream pathways (Apperley, 2015). After a 3-to-5-
year indolent chronic phase (CP), if untreated, CML progresses into accelerated 
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phase (AP) and reaches the blast phase (BP) within a year, at which point life 
expectancy drops to less than one year (Ramdass et al., 2013). Research over ten 
years has however led to improve the prognosis of CML from that of a fatal disease 
to a disorder manageable by lifelong oral medication not affecting normal lifespan 
(Apperley, 2015). 
Acute Myeloid Leukemia (AML) 
AML is characterized by infiltration of the bone marrow, blood, and other 
tissues by proliferative, clonal, aberrant, and sometimes poorly differentiated cells 
of the myeloid lineage. The vast molecular diversity behind the disease has become 
increasingly apparent over the past 15 years, although the cytogenetic 
heterogeneity of AML has been evident for more than 30 years (Longo, Döhner, 
Weisdorf, & Bloomfield, 2015). The leukemic clone is maintained by a rare 
population of LSCs that have acquired enhanced self-renewal ability, whereas the 
leukemic blasts have limited proliferative capacity (Ramdass et al., 2013). Genes 
that are commonly involved in epigenetic regulation (i.e., DNMT3A, ASXL1, IDH2, 
and TET2) were shown to be present in pre-leukemic hematopoietic stem cells and 
occur early in the evolution of AML (Krönke et al., 2013; Shlush et al., 2014; Corces-
Zimmerman, Hong, Weissman, Medeiros, & Majeti, 2014). Such ancestral pre-
leukemic stem cells have a propensity for multi-lineage differentiation, can resist 
chemotherapy, and can proliferate during remission, eventually causing relapse 
(Longo et al., 2015). Furthermore, somatic mutations in clonal hematopoiesis 
involving the same genes (DNMT3A, TET2, and ASXL1) were shown to increase with 
the subjects’ age, also showing a correlation with an increased risk of hematologic 
cancer and death (Busque et al., 2012; Jaiswal et al., 2014; Genovese et al., 2014). In 
absolute value, this risk is relatively low, and no evidence of clinical consequences 
have yet emerged (Longo et al., 2015). Prognostic factors can be divided in two 
groups: factors that are patient-related (age, comorbidities, and poor performance 
status), and factors that are disease-related (white-cell count, prior MDS or 
cytotoxic therapy for another disorder, and leukemic-cell mutations). Patient-
related factors commonly foretell treatment-related premature death, whereas 
disease-related factors predict resistance to current standard therapy. Advances in 
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healthcare have led to a noticeable decrease in the risk of treatment-related death, 
reaching considerably lower levels than the risk that the disease will show 
treatment resistance (Othus et al., 2014). Three molecular markers (NPM1 and 
CEBPA mutations and FLT3 internal tandem duplications) are currently 
recommended by the European LeukemiaNet (ELN) to be used for prognostic 
classification in clinical practice (Döhner et al., 2010), and additional markers (e.g., 
RUNX1, ASXL1, and TP53) that have consistently been associated with an inferior 
outcome are also expected to be soon included in these recommendations (Longo 
et al., 2015). 
1.2 Acute Myeloid Leukemia 
1.2.1 Classification and Clinical Manifestations 
There are 2 staging systems that are commonly used during diagnosis of AML: 
the World Health Organization (WHO) classification reviews chromosome 
translocations and evidence of dysplasia, while the French-American-British (FAB) 
classification system is based on morphology to define specific immunotypes. 
 
Table 1: French-American-British (FAB) classification of AML 
FAB subtype Name Adult AML patients (%) 
M0 Undifferentiated acute myeloblastic leukemia 5% 
M1 Acute myeloblastic leukemia with minimal maturation 15% 
M2 Acute myeloblastic leukemia with maturation 25% 
M3 Acute promyelocytic leukemia 10% 
M4 Acute myelomonocytic leukemia 20% 
M4eos Acute myelomonocytic leukemia with eosinophilia 5% 
M5 Acute monocytic leukemia 10% 
M6 Acute erythroid leukemia 5% 
M7 Acute megakaryocytic leukemia 5% 
(Table from “Acute Myeloid Leukemia Staging,” 2015) 
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Table 2: Current World Health Organization (WHO) classification of AML 
AML with Recurrent Genetic Abnormalities: 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBEB-MYH11 
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
AML with myelodysplasia-related change 
Therapy-related myeloid neoplasms 
AML, not otherwise specified: 
Undifferentiated AML (M0) 
AML with minimal differentiation (M1) 
AML without maturation (M2) 
AML with maturation (M2) 
Acute myelomonocytic leukemia (M3) 
Acute monoblastic/monocytic leukemia (M4) 
Acute erythroid leukemia (M5) 
Pure erythroid leukemia (M6) 
Erythroleukemia, erythroid/myeloid (M6) 
Acute megakaryoblastic leukemia (M7) 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
(Table from Swerdlow et al. 2008). 
1.2.2 Current Treatment Options 
The general therapeutic arsenal in patients with AML has not seen substantial 
changes in more than 30 years (Döhner et al., 2010). Initial assessment determines 
whether a patient is eligible for intensive induction chemotherapy. If intensive 
therapy results in complete remission, appropriate consolidation therapy is 
essential (Longo et al., 2015). 
1.2.2.1 Induction Therapy 
Continuous-infusion cytarabine with an anthracycline (mainly daunorubicin) 
remains the mainstay of induction therapy in AML, with no other induction regimen 
convincingly showing superiority (Longo et al., 2015). One special case is the 
addition of gemtuzumab ozogamicin, a humanized anti-CD33 monoclonal antibody 
conjugated with the cytotoxic agent calicheamicin. A recent meta-analysis of five 
randomized clinical trials has shown that although this regimen did not increase 
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patient response rates, it still reduced the risk of relapse and improved survival 
among younger and older adults with favorable-risk and intermediate-risk (but not 
adverse-risk) cytogenetic findings (Hills et al., 2014). 
1.2.2.2 Consolidation Therapy 
The two consolidation therapy regimens in AML remain conventional 
chemotherapy and hematopoietic-cell transplantation (Longo et al., 2015). 
Consolidation with Intensive Chemotherapy 
In adults who are 60 years of age or younger, an increasingly favored regimen 
is 2 to 4 cycles of intermediate-dose cytarabine. The most appropriate dose and 
number of cycles remain open issues (Longo et al., 2015). Patients with leukemic 
cells that have a more favorable ELN genetic risk profile are usually administered 
consolidation therapy with intermediate-dose cytarabine, reaching cure rates of 60 
to 70%. Patients older than 60 years of age still show highly unsatisfactory 
outcomes. Randomized trials have compared more intensive consolidation 
chemotherapy with less intensive consolidation chemotherapy, with inconclusive 
results (Schlenk, 2014). The current general recommendation is that patients with a 
favorable-risk ELN genetic profile and good performance status are entitled to 
receive repetitive cycles of an intermediate-dose cytarabine-based regimen. Such 
therapy is unlikely to benefit patients with an unfavorable genetic risk, clinically 
significant comorbidities, or both. The outcome in patients with intermediate-risk 
genetic factors also remains poor, with cure rates of only 10 to 15%. In light of such 
minimal benefits, these patients are candidates for investigational maintenance 
therapies (Longo et al., 2015). 
Allogeneic Hematopoietic-Cell Transplantation 
Post-remission therapy with allogeneic hematopoietic-cell transplantation is 
currently the strongest therapeutic approach due to pre-transplantation 
cytoreductive conditioning and the immunologic anti-leukemic graft-versus-
leukemia effect (Gupta, Tallman, & Weisdorf, 2011). Allogeneic hematopoietic-cell 
transplantation is currently only indicated in patients in which conventional 
approaches other than transplantation are unlikely to show extended complete 
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remission (Sorror et al., 2014; Armand et al., 2014; Koreth et al., 2009; Gupta et al., 
2010; Litzow et al., 2010; McClune et al., 2010; Farag et al., 2011). 
1.2.3 New Therapies 
Agents targeting a variety of cellular processes are currently being developed 
against AML, such as tyrosine kinases signaling or other signaling pathways, 
epigenetics, protein export from the nucleus, and specific antigens that are 
overexpressed on HSCs or, more specifically, on LSCs by antibody-based therapy 
(DiNardo & Cortes, 2015; Wander, Levis, & Fathi, 2014; Dawson, Kouzarides, & 
Huntly, 2012; Abdel-Wahab & Levine, 2013; Gasiorowski, Clark, Bradstock, & Hart, 
2014). 
1.2.3.1 Receptor Tyrosine Kinase Inhibitors (RTK Inhibitors) 
The high prevalence of mutations in RTK genes (FLT3 and KIT) has fuelled the 
development of RTK inhibitors. However, results with first-generation FLT3 
inhibitors have been disappointing till now (Wander, Levis, & Fathi, 2014). In 
monotherapy, they have only led to a transient decrease in blast counts. Further 
disadvantages include toxicity due to their lack of selectivity to FLT3, and the 
occurrence of FLT3 resistance mutations (Longo et al., 2015). 
1.2.3.2 New Epigenetic Therapies 
Epigenetic therapies have arisen due to the identification of numerous 
mutations in genes involved in DNA methylation and chromatin remodeling 
(Dawson, Kouzarides, & Huntly, 2012; Abdel-Wahab & Levine, 2013). One such 
therapy is the development of the oral inhibitors AG-120 and AG-221, targeting 
IDH1 and IDH2, respectively, which are two mutant metabolic enzymes frequently 
found in AML (Wang et al., 2013). Phase 1 trials have shown interesting results, in 
that AG-120 and AG-221 were shown to induce terminal differentiation of AML with 
IDH aberrancies (Stein, 2014). 
1.2.3.3 Targeting Mutation-Specific Dependencies, the Basis for 
Combination Therapies 
An example of mutation-specific dependencies is the dependence of the 
survival of IDH1-mutated and IDH2-mutated cells on anti-apoptotic B-cell CLL–
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lymphoma 2 protein (BCL2) expression (Chan et al., 2015). Accordingly, IDH1-
mutated and IDH2-mutated AML cells were more sensitive to the BCL2 inhibitor 
venetoclax; this provided the basis for combinatorial therapy. 
A further example is the discovery of BRD4, a member of the bromodomain 
and extraterminal (BET) family of bromodomain epigenetic readers, as a potential 
therapeutic target in AML (Dawson, Kouzarides, & Huntly, 2012); OTX015 and other 
BET bromodomain inhibitors are currently in clinical development (Dombret, 2014). 
1.2.3.4 Hypomethylation agents 
A second-generation hypomethylating agent (SGI-110) is a dinucleotide of 
decitabine and deoxyguanosine. It protects decitabine from inactivation by cytidine. 
It is currently being tested in a phase 3 trial in older patients who are not candidates 
for intensive therapy (Issa et al., 2015). 
1.2.3.5 Nuclear Export Receptor Inhibitors 
The major nuclear export receptor chromosome region maintenance 1 
(CRM1) is currently being targeted, since a high expression level is associated with 
short survival in AML (Kojima et al., 2013). An ongoing trial (NCT02088541) is 
currently comparing a new CRM1 inhibitor (selinexor) to specified investigator 
choices in elderly patients with relapsed or refractory AML (Etchin et al., 2013). 
1.2.3.6 New Formulations of Classic Cytotoxic Agents 
A pivotal study is currently evaluating the combination of Vosaroxin, which is 
a new anticancer quinolone derivative that inhibits topoisomerase II, in 
combination therapy with intermediate-dose cytarabine in patients with relapsed or 
refractory AML (Ravandi, 2014). Furthermore, CPX-351 is a liposomal formulation of 
cytarabine and daunorubicin packaged at a 5:1 molar ratio within liposomes that 
are 100 nm in diameter (Lancet et al., 2014). 
1.2.3.7 Antibody Therapy 
New monoclonal antibodies targeting CD33 are being developed, either as 
antibody–drug conjugates or as bi-specific antibodies (anti-CD33 and CD3). CD123, 
the trans-membrane alpha chain of the interleukin-3 receptor, preferentially 
expressed on leukemic stem cells, is a new target. CD123 is currently also under 
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investigation as a target for chimeric antigen receptor T-cell–engineered cellular 
therapy (CAR-T cell therapy) (Gill et al., 2014). Another possible target for CAR-T cell 
therapy is the expression of folate receptor β (Lynn et al., 2015). 
1.3 Where Are We Now in the Management of AML? 
The advances in our knowledge of the molecular pathogenesis in AML still did 
not make it to standard clinical practice. Several compounds are undergoing clinical 
trials, but it is unlikely that any of them will be able to cure AML as a monotherapy 
(Longo et al., 2015), necessitating the development of alternative therapies. 
1.4 Metal-Based Therapies, Metallomics and Metal-Organic 
Complexes 
The use of metal-based compounds for disease treatment is not a new 
occurrence. Already in historic times was the therapeutic potential of gold salts 
known by ancient Egyptians (Nobili et al., 2010). Furthermore, arsenic drugs, like 
arsenic trioxide (ATO), were used in traditional Chinese medicine as antiseptic 
agents, or against such diseases as rheumatoid arthritis, syphilis, and psoriasis. ATO 
was indeed one of the first suggested therapies for cancer, and represented the 
mainstay of treatment against leukemia in the 18th and 19th centuries (Dilda & Hogg, 
2007; Tapio & Grosche, 2006). It is only in 1969 that a “metal revolution” in the 
treatment of cancer took place, opening a new era in metal-based cancer therapies 
with the discovery of cisplatin (Rosenberg et al., 1969). Today, cisplatin and its 
newer-generation platinum analogs carboplatin and oxaliplatin are still among the 
most important chemotherapeutic agents (Kelland, 2007; Jungwirth et al., 2011). 
Following the success of cisplatin, other metal-based coordination complexes were 
studied, including metals such as ruthenium, gold, titanium, copper, rhodium, 
vanadium, lanthanum and cobalt, generating some good candidate therapies that 
are currently undergoing preclinical or clinical evaluation (Jungwirth et al., 2011).  
The metallome is a term coined in analogy to the proteome. It refers to the 
distribution of free metal ions in cellular compartments, and is defined as describing 
all the biologically active compounds of an organism that contain a metal atom 
(Williams, 2001; Groessl & Hartinger, 2013). Accordingly, “metallomics” is the study 
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of the metallome, or the comprehensive study of the integrity of metal and 
metalloid species within a cell or tissue (Szpunar, 2005), involving techniques for the 
detection of metal-containing biomolecules, which have been extended to the 
research use in the detection of synthetic metal-based small molecules (Groessl & 
Hartinger, 2013). Thus, metallomics and metalloproteomics are fields addressing 
the role, uptake, transport and storage of trace metals essential for protein function 
(Shi & Chance, 2008). 
Metal-based small molecules could further be classified according to their 
chemical properties, thus differentiating between the metal coordination 
complexes (also known as metal-organic compounds), defined as molecules that 
possess a metal center to which ligands are bound, and the organometallics, which 
feature at least one carbon-metal covalent bond (Groessl & Hartinger, 2013; 
Jungwirth et al., 2011). 
1.4.1 Platinum in Cancer Therapy 
The discovery of cisplatin by chance by Rosenberg in the 1960’s while studying 
the effect of electrical currents on bacterial growth using platinum electrodes, led 
to it reaching and preserving a prominent place in cancer therapy, which has 
contributed to our extended present knowledge of its target as well as off-target 
effects (Hannon, 2007). Cisplatin has a Pt(II) metal center coordinated to two 
ammonia and two chloride ligands in a cis conformation (Figure 3), and its primary 
action is by intercalating into the DNA and bending it. Cisplatin remains in its neutral 
form after injection in the serum, and is believed to only alter it after cellular 
uptake, whereby one or both Cl ligands can be displaced by one or two aqua 
ligands, thus rendering the complex cationic. These cationic forms of cisplatin can 
react with DNA bases, most commonly the N7 of guanine, followed by that of 
adenine. Structurally, the most frequently observed intercalation type is through 
the formation of a bifunctional adduct between two consecutive bases on the same 
strand (G-G 1,2-intra-strand adduct in > 70% of the cases), thus causing a 45° nick in 
the double-strand (Takahara, Rosenzweig, Frederick, & Lippard, 1995). Adverse 
effects of the clinical use of cisplatin include nephrotoxicity, nausea, vomiting, as 
well as numbness in the extremities. Some of these side-effects are thought to be 
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due to the platination of sulfur residues on proteins, which could be countered by 
the co-administration of sulfur-containing “rescue agents” (Hannon, 2007). 
 
Figure 3: Classical cis-platinum compounds 
(From Hannon, 2007) 
Already early in the development of platinum agents, trans-platinum 
compounds were found to be inactive, thus rapidly rendering the cis conformation a 
dogma for activity (Rosenberg, Van Camp, Grimley, & Thomson, 1967). The success 
of cisplatin fuelled a fast-track investigation of several other platinum-containing 
compounds, and led to the early adoption of the general principle that a square-
planar Pt(II) center coordinated to two amines in cis and two leaving groups is 
required for activity. Other agents that abide by this general rule of “theme and 
variation” of cisplatin have since been able to make it to the market (carboplatin, 
oxaliplatin and nedaplatin, Figure 3). This rule has however later been shown to give 
a high probability, but not to be a prerequisite for activity, thus leading the way for 
the development of non-classical platinum-centered agents that do not abide by 
the classical structure-activity paradigm (Hannon, 2007; Jakupec, Galanski, Arion, 
Hartinger, & Keppler, 2008). Such non-classical agents include three distinct classes 
of trans-platinum (II) complexes: the first class containing pyridine ligands, the 
second class containing an alkylamine and an isopropylamine, and the third class 
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containing iminoether ligands (Figure 4) (Hannon, 2007; Farrell et al., 1989; 
Montero et al., 1999; Coluccia et al., 1993). These non-classical trans-platinum 
agents, while showing in-vitro activity similar to cisplatin, have also shown activity 
against cisplatin-resistant cell lines. Besides, due to their trans conformation, the 
types of DNA lesions that they cause are inherently different from those described 
with cisplatin. In spite of their documented activity, these agents have not yet been 
assessed in the clinic (Hannon, 2007). 
 
Figure 4: Classes of active non-classical trans-platinum (II) compounds 
Left: pyridine-containing; Center: isopropylamine-containing; Right: iminoether-containing. 
(From Hannon, 2007) 
One further class of active non-classical platinum agents includes the di- and 
tri-platinum compounds developed by Farrell (2004), whereby the metal centers are 
linked by flexible diamine chains. In addition to being multinuclear, these 
compounds are also poly-cationic and do not contain platinum centers with leaving 
groups in cis. In pre-clinical evaluation, these compounds have shown noticeably 
increased activity compared to cisplatin against a broad array of tumor types, 
including those resistant to cisplatin. Their action has been shown to feature 
bifunctional long-range adducts including both inter- and intra-strand cross-linkage, 
as well as a DNA conformation change from a right-handed (B) to a left-handed (Z) 
double-helix (Kloster, Hannis, Muddiman, & Farrell, 1999). One agent of this class, 
BBR3464 (Figure 5) has undergone phase II clinical trials against gastric or gastro-
esophageal adenocarcinoma and sensitive or refractory small cell lung carcinoma, 
however without success (Jodrell et al., 2004; Hensing et al., 2006). 
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Figure 5: Structure of BBR3464 
(From Hannon, 2007) 
1.4.2 Ruthenium in Cancer Therapy 
One alternative to breaking the cisplatin dogma is by examining the activity 
conferred by different metal centers. Ruthenium is among the best-studied non-
platinum metal complexes with anti-cancer activity, and is particularly attractive, as 
it presents several advantages over platinum in the development of metal-based 
antitumor therapies. These include: (i) a well-developed preparative coordination 
chemistry allowing for the synthesis of numerous novel complexes, (ii) a 
comparable rate of ligand exchange to that of platinum, (iii) an octahedral 
coordination geometry, as opposed to the square planar geometry of platinum, 
implying a different mode of function, (iv) accessibility of three oxidation states 
under physiological conditions (+2, +3 and +4), (v) the possibility to form pro-drugs 
at the +3 oxidation state that can later be reduced at the target and (vi) the ability 
to mimic iron on the binding sites to biomolecules such as human serum albumin 
and transferrin, thus markedly decreasing the toxicity of ruthenium compounds in 
comparison to platinum (Jakupec, Galanski, Arion, Hartinger, & Keppler, 2008; 
Bergamo, Gaiddon, Schellens, Beijnen, & Sava, 2012). 
The lower general toxicity of some ruthenium-containing compounds could 
also be due to a mechanism of “activation by reduction”, whereby compounds 
administered in the Ru(III) oxidation state are reduced to the kinetically more 
reactive Ru(II). This mechanism is thought to take place in the reductive 
microenvironment observed in rapidly dividing solid tumors where hypoxic tumor 
cores arise due to insufficient angiogenesis (Jakupec et al., 2005; Schluga et al., 
2006). 
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On the other hand, all major genes involved in iron metabolism have been 
shown to respond to oxygen deprivation, which could lead to the hypothesis that 
hypoxia generally sensitizes tumor cells to compounds interfering with iron-
dependent processes. In particular, hypoxia has been shown to induce elevated 
transferrin receptor expression in tumor cells, suggesting that hypoxia-activated 
pro-drugs capable of transferrin-mediated cellular uptake attain their tumor 
selectivity not only by a dual, but a cooperative mechanism (Tacchini, Bianchi, 
Bernelli-Zazzera, & Cairo, 1999). In this sense, the tested compounds should be 
much more readily reducible under the hypoxic conditions of tumors than under 
the normoxic conditions in normal tissues, in order for them to warrant tumor-
selective activity and a high therapeutic index. For Ru(III) compounds, an 
appropriate redox potential is therefore probably a more important parameter than 
cytotoxic potency under normal conditions. In this sense, a high cytotoxicity must 
be considered disadvantageous, since it might reflect an easy reducibility under 
normoxic conditions (Jakupec et al., 2005). 
Two Ru(III) compounds are currently undergoing clinical evaluation: NAMI-A 
and KP1019 (Figure 6). The first to enter clinical trials was NAMI-A (Rademaker-
Lakhai, van den Bongard, Pluim, Beijnen, & Schellens, 2004). NAMI-A is an anionic 
complex with an octahedral geometry where the Ru(III) center is bound to one 
imidazole ligand and one DMSO ligand, with four chlorides completing the 
octahedral coordination. The role of this compound in cancer therapeutic 
development is remarkable due to the fact that it is not especially active against 
cancer cell lines or primary tumors, but shows anti-metastatic activity (Hannon, 
2007). Although NAMI-A can bind DNA, its mechanism of action is believed to be 
different. It has been shown to possess anti-angiogenic activity due to its ability to 
scavenge nitric oxide (NO) liberated by epithelial cells. Furthermore, its anti-invasive 
properties arise from its interaction with extracellular or external cell membrane 
receptor proteins. (Jungwirth et al., 2011; Bergamo, Gaiddon, Schellens, Beijnen, & 
Sava, 2012). 
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Figure 6: Structures of NAMI-A and KP1019 
(From Bergamo, Gaiddon, Schellens, Beijnen, & Sava, 2012) 
The second Ru(III) complex to make it to clinical trials, KP1019, is active 
against primary tumors despite its structural similarity to NAMI-A. KP1019 causes 
apoptosis via the mitochondrial pathway, and is believed to act as a pro-drug, while 
its final active species has not yet been elucidated. Under physiological conditions, 
the complex exchanges at least one chloride to an aqua ligand, and the complex can 
bind to serum albumin as well as transferrin. Human serum albumin can bind up to 
four of these ruthenium complexes and may act as a “reservoir” of agent. 
Transferrin, on the other hand, can bind two Ru centers in its two iron binding 
pockets, a phenomenon that has been shown in crystallographic data with KP1019. 
The acidic pH normally found in endosomes, responsible for releasing iron from 
transferrin inside the cell, has been similarly shown to release KP1019, thus 
indicating that this drug can use the natural iron transport systems effectively to 
locate itself inside the cell. Once inside the cell, KP1019 has been shown to 
preferentially localize to the guanine and adenine residues on DNA, as well as to 
protein histidine residues (Hannon, 2007; Bergamo, Gaiddon, Schellens, Beijnen, & 
Sava, 2012). 
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More recently, two further classes of ruthenium anticancer agents have been 
developed, centered around Ru(II) arene organometallic compounds with a “piano 
stool” conformation: the Sadler class and the RAPTA (Figure 7). Similar to NAMI-A 
and KP1019 described above, one of these two new classes (the Sadler class) acts as 
a cytotoxic DNA-intercalating agent, and the other class represented by the RAPTA 
compounds has shown anti-metastatic activity (Hannon, 2007; Jakupec, Galanski, 
Arion, Hartinger, & Keppler, 2008; Jungwirth et al., 2011; Bergamo, Gaiddon, 
Schellens, Beijnen, & Sava, 2012). 
 
Figure 7: Ru(II) arene organometallic classes with a “piano stool” conformation 
Left: A representative of the cytotoxic Sadler class; Right: A representative of the anti-metastatic RAPTA class. 
(From Hannon, 2007) 
Furthermore, a molecule with the formula [Δ,Δ-μ-C4(cpdppz)-(phen)4Ru2]4+ 
(Figure 8) formed by the dimeric (dinuclear) linkage of two molecules of an 
intercalating Ru(II) coordination complex with tris-bidentate ligands previously 
described (Hiort, Lincoln, & Norden, 1993; Nair & Murphy, 1998) has been reported 
to act as a bis-intercalator (Onfelt, Lincoln, & Nordén, 2001). The complex contains 
two [Ru(phen)2(dppz)]2+ motifs linked between their diphenylpiperazine (dppz) 
groups, precisely where the monomeric (mononuclear) compounds normally 
intercalate into DNA. Therefore, in order to exert its action, this complex needs to 
thread through the DNA, which has been shown to be the case, since both dppz 
groups have been shown to intercalate from one groove, while the bridging chain 
lies in the other groove. This compound has been shown to exert potent activity in 
some cancer cell lines, with a three- to four-fold increase in potency as compared to 
the mononuclear form (Onfelt, Lincoln, & Nordén, 2001). 
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Figure 8: Structure of the threading bis-intercalator [Δ,Δ-μ-C4(cpdppz)-(phen)4Ru2]
4+  
(From Hannon, 2007) 
The above compound (Figure 8) is of particular interest to us in the present 
study, due to the structural analogy between its mononuclear form and the 
complexes that we are developing, and whose activity we are describing against 
AML cell lines below. 
1.4.3 Ru photochemistry and photodynamic therapies 
The focus of photodynamic therapy (PDT) is to kill undesirable cells in the 
body through the activation of photosensitive agents by light. The ability of PDT 
agents to interact with cell components, such as biopolymers or DNA or cell 
membranes, determines their activity. Light-induced electron transfer between the 
excited state of the PDT molecule and DNA is one possible mechanism through 
which these therapies could be used to damage DNA. Some compounds also allow 
for photo-inducible ligand substitution, whereby a metal complex could either 
release a biologically active substance or itself bind to molecular targets (Clarke, 
2003). 
For a complex to be useful in PDT, it should have a stable enough ground state 
that is generally nontoxic. The complex should also exhibit well characterized 
photophysical properties and a readiness for photochemical conversion to the 
active form. Besides, since wavelengths in the higher energy spectrum of visible 
light (640-850 nm) are readily absorbed by mammalian tissues, PDT should ideally 
strongly absorb at those relatively long wavelengths (Clarke, 2003). 
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Anti-cancer photodynamic therapies usually primarily target DNA, namely 
through one of four possible mechanisms: (i) ionic binding between a positively-
charged complex and the poly-anionic DNA, (ii) non-covalent hydrophobic 
interactions, (iii) DNA intercalation and (iv) covalent binding (Manning, 1978; 
Manning & Ray, 1998; Yang, Wu, Wang, Ji, & Tian, 1997). It should further be 
highlighted that Ru(II) complexes with N-heterocyclic ligands are especially 
attractive as potential PDT agents with regards to their readiness for metal-to-
ligand charge transfer transitions and long-lasting excited states (Pacor et al., 1991; 
Clarke, 2003). 
1.5 Study Objectives 
In this study, we aim to establish a photochemical model based on Ru(II) 
complexes with N-heterocyclic ligands for effectively targeting AML. We will first 
show potency and establish a structure-activity relationship of the ligands and 
precursor complexes against AML, second, we will determine the type of cell death 
observed and perform a cell cycle analysis of the effect of the compounds, then we 
will use the model established earlier in order to examine the photochemical 
potential of the complexes, determine the level of light potentiation and examine 
the type of cell death and perform a cell cycle analysis. The ultimate goal of the 
project is to lay the foundation stone for later approaches to selectively target AML 
with complexes based on this model. 
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CHAPTER TWO 
Materials and Methods 
2.1  Cells and Cell Lines 
Human AML cell lines HL60, U937, ML1, ML2, Mono-Mac-1, Mono-Mac-6, KG-
1, TF1-vRaf, TF1-vSrc and TF1-HaRas were obtained from the American Type Culture 
Collection (ATCC) and grown as described previously in RPMI 1640 supplemented 
with 10% FBS and 5% Penicillin/Streptomycin at 37°C, 5% CO2 (Pellizzari et al., 
1999). 
2.2  Compounds 
Compounds were synthesized by Dr. Rony Khnayzer and his research group at 
the Lebanese American University. They were provided in the lyophilized powder 
form, dissolved and aliquoted in stocks of 1, 2, 5 or 10 mM in DMSO. Aliquots were 
stored at -80°C for a maximum of 2 months or 3 freeze-thaw cycles. 
 
Figure 9: Ligands, Ru(II) precursor complexes, and ligand-free Ru(II) control 
Ligands: L-I: 1,10-Phenanthroline; L-II: 4,7-Diphenyl-1,10-phenanthroline; L-III: 4,7-Diphenyl-1,10-
phenanthroline disulfonic acid; L-IV: 2,2-Bipyridine; Ru(II) precursor complexes: Ru-I: [Ru(II)(1,10-
phenanthroline)2Cl2]; Ru-II: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2Cl2]; Ru-III: [Ru(II)(4,7-diphenyl-1,10-
phenanthroline-disulfonate)2Na2]
2-; Ru-IV:[Ru(II)(2,2'-bipyridine)2Cl2]; Ligand-free Ru(II) control: Ru-C: 
RuCl2(DMSO)4. 
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Figure 10: Photochemically-active Ru(II) final complexes 
Ru-II3: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)3]
2+; Ru-II2-III: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2(4,7-
diphenyl-1,10-phenanthroline-disulfonate)]; Ru-II-III2: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)(4,7-diphenyl-
1,10-phenanthroline-disulfonate)2]
2-; Ru-III3: [Ru(II)(4,7-diphenyl-1,10-phenanthroline-disulfonate)3]
4-. 
2.3  Proliferation Inhibition Assay (Cytotoxicity) 
Sensitivity of AML cell lines to the compounds listed above was determined 
using a proliferation inhibition assay as described previously (Abi-Habib et al., 2005). 
Briefly, aliquots of 2 to 3 x104 cells/well in 100 µL of cell culture medium were 
plated in a flat-bottom 96-well plate (Corning Inc. Corning, NY). The cells were 
allowed to recover for 24h, before 50 µl of compound in media were added to each 
well to yield concentrations ranging from 200 µM to 3 nM. In the experiments 
involving light activation, the plates containing cells and compounds were exposed 
to blue light (430-490 nM) at 10 V for 30 min at room temperature. Following an 
incubation at 37°C/5% CO2 till the appropriate time-point of the experiment, 50 µL 
of XTT cell proliferation reagent (Roche, Basel, Switzerland) were added to each well 
4h before the end of the intended incubation period, and the cells were incubated 
as above for the remaining 4h. Absorbance was then read at 450 nm using a 
microplate reader (Thermo Fisher Scientific, Waltham, MA). Nominal absorbance 
and percent maximal absorbance were plotted against the log of concentration and 
a non-linear regression with a variable slope sigmoidal dose-response curve was 
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generated along with IC50 using GraphPad Prism 5 software (GraphPad Software, 
San Diego, CA).  
2.4  Metal Uptake by Flow Cytometry 
Cellular uptake of auto-fluorescent Ru-containing complexes was measured 
by flow cytometry. AML cells were plated in 24-well plates at a density of 3x105 cells 
in 250 µL cell culture medium in each well. The cells were allowed to recover for 
24h at 37°C/5% CO2, then 250 µL of compounds diluted in medium were added. The 
plates were incubated at 37°C with 5% CO2 for the needed amount of time before 
being harvested and run for fluorescence detection on the FL3-H channel on a C6 
flow cytometer (BD Accuri, Ann Arbor, MI). The threshold was set to 500,000 on 
FSC-H, and 5,000 to 20,000 events were run per sample. 
2.5  Type of Cell Death Determination 
The type of cell death was determined using fluorescin Isothiocyanate (FITC)-
conjugated Annexin V antibody (Annexin V-FITC) and PI staining (apoptosis 
detection kit, Abcam, Cambridge, MA) as described previously (Abi-Habib et al. 
2005). The presence of active caspases in cells was detected using a cell permeable, 
FITC-conjugated active caspase inhibitor (R&D systems) on flow cytometry as 
described previously (Abi-Habib et al, 2005). Briefly, 3x105 cells/well were plated in 
250 µL of culture medium in a 24-well plate and were left to recover for 24 hours at 
37°C/5% CO2. They were later incubated with either 250 µL of media alone (control 
cells) or media containing different concentrations of L-II, Ru-II, Ru-II3 or Ru-II2-III for 
24 and 48 hours at 37°C/5% CO2. Cells were then either harvested and incubated 
with FITC-conjugated annexin V antibody (2.5 mg/ml) and PI (5 mg/ml) in antibody 
binding buffer for 45 minutes at 37°C, or incubated with a FITC-conjugated active 
caspase inhibitor (ApoStat Apoptosis Detection Kit, R&D Systems, Abingdon, 
England) for 60 minutes then harvested. Cells were then read using a C6 flow 
cytometer (BD Accuri, Ann Arbor, MI). Annexin V/PI data was analyzed on FL1-H 
versus FL2-H scatter plot and caspase activation was detected on FL1-H. Unstained 
cells were used as negative control. Cells were gated on width versus forward 
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scatter. Cells had to show positive annexin V staining, negative PI staining and 
positive active caspase staining to be considered apoptotic, while cells positive for 
both annexin V and PI staining and negative for active caspase staining were 
considered non-apoptotic/necrotic. 
2.6  Cell Cycle Analysis 
The impact of L-II, Ru-II, Ru-II3 and Ru-II2-III treatment in the dark on the cell 
cycle of AML cells was determined using Propidium Iodide (PI)-staining on flow 
cytometry as described previously (Abi-Habib et al, 2005). Briefly, cells (106 
cells/well in 1 mL growth medium) incubated with different concentrations of L-II, 
Ru-II, Ru-II3 or Ru-II2-III or media alone in 6-well plates (Corning Inc. Corning, NY) for 
6, 24 and/or 48 hours at 37°C/5% CO2, were harvested and fixed in 70% ethanol for 
a minimum of 24 hours at -20°C. Cells were then incubated in 500 µL PI staining 
solution (50 μg/ml) for 40 minutes at 37°C. Samples were then read on a C6 flow 
cytometer (BD Accuri, Ann Arbor, MI) and cell DNA content was measured on FL2-A. 
The target cell population, excluding fragments and doublets, was gated on width 
versus forward scatter. Percent of cells in G0/G1, S and G2/M phase as well as 
percent cells in pre-G0/G1 phase (dead) was determined in control cells and in cells 
treated with the different concentrations of L-II, Ru-II, Ru-II3 and Ru-II2-III at the 
different time points.  
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CHAPTER THREE 
Results 
 
3.1  Cytotoxic Effect of the Ligands and Ru(II) Precursor 
Complexes on a Panel of Human AML Cell Lines 
 
Figure 11: Cytotoxic effect of the free ligands and their corresponding Ru(II) precursor complexes on three 
representative AML cell lines at 48h 
Nonlinear regression curves for the cytotoxicity of L-I & Ru-I (A), L-II & Ru-II (B), L-III & Ru-III (C), L-IV & Ru-IV (D) 
& Ru-C (E) vs DMSO (solvent) on HL-60 (1), ML2 (2) and TF1-vRaf (3). % v/v DMSO at the highest dose of each 
compound tested is indicated between brackets in the legend of each graph. 
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The phenanthroline- and bipyridine-derived ligands and their respective Ru(II) 
precursor complexes (Figure 9) were tested on a panel of 9 AML cell lines. 
Representative data against three cell lines, two showing more sensitivity (HL-60 
and ML2) and one showing more resistance (TF1-vRaf) is shown in Figure 11. High 
activity was observed with both L-I and L-II as well as Ru-II on the majority of the 
panel with IC50 values in the low µM range for L-I and Ru-II and reaching the nM 
range for L-II (Table 3 & Figure 12). No significant activity was observed with either 
L-III, Ru-III, L-IV, Ru-IV or the ligand-free metal control Ru-C. The effect observed 
with the active ligands (L-I & L-II) was at least one order of magnitude higher than 
that observed with their respective Ru(II) precursor counterparts (Table 3 & Figure 
12). 
 
 
Figure 12: L-I, L-II and Ru-II show high potency against AML cell lines, and the ligand-free Ru-C is biologically 
inert 
IC50 48h (µM) of the different compounds on a panel of 9 AML cell lines. IC50 values < 20 µM considered to show 
high potency whereas high IC50 values (> 20 µM) considered to show resistance or masking of low activity by 
DMSO effect (solvent). 
 
A cell viability time-course carried-out to test the time-dependent cytotoxic 
effect of L-II and Ru-II on ML2 (3h, 6h, 12h, 24h, 48h, 72h & 96h) has shown a 
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noticeable difference between L-II and Ru-II, whereby the onset of cell death due to 
L-II at high doses appeared to start at earlier time-points, when the Ru-II curve was 
still indiscernible from the DMSO (solvent) curve (Figure 13). It should also be 
pointed that the data presented here shows an experiment in which L-II had an 
even lower % v/v of DMSO than Ru-II at the highest dose tested (4% vs. 5%). 
 
Figure 13: L-II cytotoxic effect starts at earlier time-points than Ru-II with maximum effect reached at 72h for 
both 
Cytotoxicity time-course for L-II & Ru-II vs DMSO at 3h (A), 6h (B), 12h (C), 24h (D), 48h (E), 72h (F) and 96h (G). 
Furthermore, flow cytometric detection of the uptake of Ru-II by making use 
of its auto-fluorescence (detectable on the FL3-H channel) has shown clearly 
detectable uptake at early time-points post-treatment (Figure 14). This onset of 
uptake precedes the cytotoxic effect observed later, and uptake is still detected at 
later time-points (24h & 48h [Figure 14] and 72h [data not shown], thus confirming 
that the cytotoxic effect observed is dependent on the uptake of the complex. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Cellular uptake of Ru-II begins at early time 
points 
Ru-II (emission fluorescence near 600 nm) detected 
intracellularly on FL3-H by flow cytometry at 1, 2, 4, 24 & 
48h post treatment. 
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3.2  Type of Cell Death Determination and Cell Cycle Analysis of 
the Action of the Free Ligands and Ru(II) Precursors 
Type of cell death determination by flow cytometry (Annexin V / PI staining 
and caspase cleavage assay) at 24h and 48h has shown apoptosis with both L-II and 
Ru-II against ML2 (Figure 15 & 16). The Annexin V / PI staining for type of cell death 
determination involves the use of a fluorescently-labeled Annexin V, a calcium-
dependent phospholipid-binding protein that specifically targets phosphatidylserine 
(PS), a phospholipid membrane component that in normal conditions is actively 
kept facing the cytosolic side of the membrane by the enzyme flippase. In the case 
of apoptosis, PS is no longer restricted to the cytosolic domain by flippase, and 
spontaneously flips to the extracellular domain, this acting as signals for 
macrophage recognition and engulfment. In the Apoptosis Detection Kit, 
fluorescently-labeled Annexin V can be detected by flow cytometry on the FL1-H 
channel (x axis in figure 15 & 16, A, B, C, E, F & G). Propidium iodide (PI) is an auto-
fluorescent DNA intercalating agent which could be detected on the FL2-H channel 
(y axis in figure 15 & 16, A, B, C, E, F & G) to show dead cells, whose cytoplasm has 
become permeable to PI. Accordingly, cells that stain positive for Annexin V while 
showing to be negative to PI would be early apoptotic, whereas cells that stain 
double-positive are dead cells, and could either be late-apoptotic or necrotic. In 
order to segregate between late-apoptotic and necrotic cells, an examination of 
apoptotic markers is necessary. 
The caspase cleavage assay (or caspase activity assay) for flow cytometry, 
used in our experiments to help detect apoptosis, involves an approach termed 
fluorescence inhibition of caspase (FLICA), that makes use of a fluorescent caspase 
pan-inhibitor that binds covalently and irreversibly to the reactive cysteine residues 
of active caspases in order to inhibit enzymatic activity. The level of fluorescence of 
the fluorescent caspase inhibitor is measured on the FL1-H channel (x axis in figures 
15 & 16, D & H). 
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Figure 15: Cell death by L-II is apoptotic 
Annexin-PI (A –C & E-G) & Caspase Activation (D & H) at 24h (A-D) and 48h (E-H). ML2 Control (A & E). L-II – 1.5 
µM (B & F) & 3 µM (C & G). Normal cell population (LL), early-apoptotic cell population (LR), late-apoptotic / 
necrotic cell population (UR). 
 
Figure 16: Cell death by Ru-II is apoptotic 
Annexin-PI (A-C & E-G) & Caspase Activation ( D & H) at 24h (A-D) and 48h (E-H). ML2 Control (A & E). Ru-II – 7.5 
µM (B & F) & 15 µM (C & G). 
Furthermore, cell cycle analysis (PI staining) at 6h and 24h has shown a higher 
propensity for G0-G1 cell cycle arrest with L-II at both time-points, whereas this was 
observed only at the 6h time-point with Ru-II, and was later followed by a higher 
propensity for sub-G1 arrest / cell death at 24h (Figure 17). This assay is a semi-
quantitative approach for the detection of the amount of DNA present in fixed cells. 
In control experiments, two peaks are usually observed, with a plateau in-between, 
with the second peak corresponding to double the value of the first peak. This 
differentiates cells that are in the G0-G1 phase of the cell cycle (first peak) from 
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those that have passed the replication phase (G2-M), and the plateau corresponds 
to cells that were undergoing DNA replication at the time of fixation. 
 
Figure 17: L-II causes G0-G1 cell cycle arrest at 6h and 24h; Ru-II causes G0-G1 cell cycle arrest at 6h followed 
by cell death at 24h 
Cell Cycle Analysis – PI Staining at 6h (A-E) and 24h (F-J). ML2 Control (A & F). L-II – 1.5 µM (B & G) & 3 µM (C & 
H). Ru-II – 7.5 µM (D & I) & 15 µM (E & J). M1: G0-G1; M2: G2-M; M3: S; M4: Sub-G1. 
 
3.3  Cytotoxicity of the Final (Tris-) Complexes in the Dark 
 
Figure 18: Cytotoxic effect of the final Ru(II) complexes and their corresponding ligands and precursors on 
three representative AML cell lines at 72h in the dark 
Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2 & Ru-III3 vs 
DMSO on HL-60 (1), ML2 (2) & TF1-vRaf (3). Ligands, Precursors & Final complexes (A), Ligands & Precursors 
alone (B), Final complexes alone (C). 
33 
 
 
Figure 19: Cytotoxic effect of the final Ru(II) complexes vs. ligands and precursors on a panel of AML cell lines 
at 72h in the dark 
Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2 & Ru-III3 vs 
DMSO on HL-60 (A), MonoMac1 (B), TF1-vRaf (C), ML2 (D), MonoMac6 (E) & U937 (F). 
 
Figure 20: L-II and Ru-II and the final complexes that have more L-II ligands conjugated (Ru-II3 & Ru-II2-III) 
show significant potency against AML cell lines in the dark 
IC50 48h (µM) of the different compounds on a panel of 6 AML cell lines. IC50 values < 25 µM considered to show 
high potency whereas high IC50 values (> 25 µM) considered to show resistance. # Apparent activity of Ru-II-III2 
was later shown to be due to its initial synthesis involving the non-bio-compatible counter-ion phosphorus 
trifluoride PF3, and is thus non-significant. 
Cell viability experiments were carried-out on the final complexes on a panel 
of AML cell lines (Figure 18, 19 & 20). Of the four complexes, only the ones not 
having a net negative charge (Ru-II3 and Ru-II2-III) have shown significant activity. It 
should be noted, however, that in Figures 18, 19 and 20, Ru-II-III2 also appears to be 
active. This however is due to the fact that this compound was first synthesized 
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using a method that stabilizes the complex with a counter-ion other than sodium 
(phosphorus trifluoride: PF3), which was at the beginning not properly detected in 
the chemical characterization and purification steps. PF3 is not a bio-compatible 
counter-ion and the effect observed in Figure 18, 19 and 20 was shown to be due to 
it. This synthesis method also caused Ru-II-III2 to fall out of solution upon mixing 
with the cell culture medium (aqueous) for dilution, while it was perfectly soluble in 
the aliquots in DMSO. The collaborating chemists were later able to re-synthesize 
this compound with a proper bio-compatible counter-ion that also allowed keeping 
the complex in a soluble state upon dilution with culture medium. This “rescued” 
complex was later used for all subsequent experiments, and has shown no 
significant activity in the dark (Figures 26, 27 & 28 and Table 4). 
Furthermore, uptake of all final complexes was shown as described above, 
and they could all be detected at 1h and up-to 96h post-treatment (data not 
shown). With Ru-II3, however, we were even able to clearly detect its uptake only 
30 seconds post-treatment, due to its stronger auto-fluorescence in comparison to 
the other complexes (Figure 21). 
 
Figure 21: Cellular uptake of Ru-II3 is detectable 30 seconds post treatment 
Ru-II3 (emission fluorescence near 600 nm) detected intracellularly in ML2 on FL3-H by flow cytometry at 30 sec 
post treatment. 
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3.4  Type of Cell Death Determination and Cell Cycle Analysis of 
the Action of the Final Ru(II) Complexes Active in the Dark 
Type of cell death determination at 24h and 48h and cell cycle analysis at 6h, 
24h and 48h without photo-activation (as described above), was carried-out on the 
two Final complexes that showed activity in the dark.  
Cell death by Ru-II3 in the dark was shown to be predominantly non-apoptotic 
(only marginal Annexin V positive / PI negative population at the high dose at 48h as 
well as low level of caspase activation in the same sample) (Figure 22), whereas cell 
death by Ru-II2-III appeared to show no signs of apoptosis (Figure 24). 
Cell cycle analysis did not show significant G0-G1 arrest with either complex at 
any of the tested time-points, while both complexes showed sub-G1 arrest 
(indicative of cell death) at the high dose at 48h (Figures 23 & 25). 
 
Figure 22: Cell death by Ru-II3 in the dark is predominantly non-apoptotic 
Annexin-PI (A-C & E-G) & Caspase Activation ( D & H) at 24h (A-D) and 48h (E-H). ML2 Control (A & E). Ru-II3 – 
2.5 µM (B & F) & 5 µM (C & G). 
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Figure 23: Ru-II3 causes a significant shift of ML2 cells to a sub-G1 cell population at 48h at the high dose in 
the dark 
Cell Cycle Analysis – PI Staining at 6h (A-C), 24h (D-F) & 48h (G-I). ML2 Control (A, D & G). Ru-II3 – 2.5 µM (B, E & 
H) & 5 µM (C, F & I).  
 
Figure 24: Cell death by Ru-II2-III in the dark is non-apoptotic 
Annexin-PI (A-C & E-G) & Caspase Activation ( D & H) at 24h (A-D) and 48h (E-H). ML2 Control (A & E). Ru-II2III – 
7 µM (B & F) & 14 µM (C & G). 
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Figure 25: Ru-II2-III causes a significant shift of ML2 cells to a sub-G1 cell population at 48h at the high dose in 
the dark 
Cell Cycle Analysis – PI Staining at 6h (A-C), 24h (D-F) & 48h (G-I). ML2 Control (A, D & G). Ru-II2-III – 7 µM (B, E 
& H) & 14 µM (C, F & I). 
 
3.5  Cytotoxicity of the Final (Tris-) Compounds with or without 
Light Activation against ML2 
The compounds were tested again in the absence of light on ML2 (this time 
with the “salvaged” Ru-II-III2), as well as with light exposure as described above at 
0h, 3h, 6h, 12h and 24h post-treatment. As previously shown, significant activity in 
the dark was shown only with Ru-II3 and Ru-II2-III. Besides, data of light-activation 
at 0h post-treatment appeared to cause widespread loss of viability, even in the 
samples exposed to the solvent (DMSO) alone, with only control cells that were 
exposed to neither the complexes nor the solvent maintaining proper viability. This 
indicates that the disseminated cell death observed upon light-activation is caused 
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by the DMSO reacting in ways not previously documented. This “DMSO effect” 
started diminishing with light exposure at later time-points, and the curves of the 
solvent and compounds became significantly different as of the 6h time-point 
(Figure 26).  
 
Figure 26: Light significantly potentiates the effect of all final complexes 
Nonlinear regression curves for the cytotoxicity of Ru-II3, Ru-II2-III, Ru-II-III2 & Ru-III3 vs DMSO (solvent) on ML2 
in the dark (A), with light activation at T=0h (B), at T=3h (C), at T=6h (D), at T=12h (E) and at T=24h (F). All cell 
viability readings were carried-out at 72h. 
 
Figure 27: Light exerts maximal significant effect if flashed 6h post-treatment, and potentiation diminishes at 
later time-points 
Nonlinear regression curves for the cytotoxicity of Ru-II3 (A), Ru-II2-III (B), Ru-II-III2 (C) & Ru-III3 (D) on ML2 in the 
dark, with light-activation at T=6h, 12h and 24h post-treatment. All cell viability readings were carried-out at 
72h. 
Data at the 6h time-point shows marked potentiation of all complexes 
compared to their activities in the dark, reaching at least one order of magnitude 
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potentiation of the complexes already showing activity in the dark, and more than 
two orders of magnitude for the non-potent ones in the dark (Figures 27 & 28 and 
Table 4). 
 
Figure 28: IC50 values in the nM range following activation all final complexes at 6h (and most at 12h) post-
treatment 
 
The Photo-toxicity Index is the ratio of the IC50 value in the dark to that in the light.  
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CHAPTER FOUR 
Discussion 
 
4.1  Establishing a Structure-Activity Relationship in the Dark 
Cytotoxicity experiments were first carried-out on all phenanthroline- and 
bipyridine-derived free ligands and their corresponding Ru(II) metal complexes, as 
well as on the ligand-free Ru(II) metal control (Figures 11 & 12) in order to 
determine whether significant activity against the panel of AML cell lines could be 
detected. 
L-II & Ru-II are bulkier and more hydrophobic than L-I and Ru-I, respectively. L-
III and Ru-III, on the other hand, have the same general structure as L-II and Ru-II, 
respectively, except that they also feature negatively-charged groups. L-III and Ru-III 
were synthesized by adding sulfonate groups to the phenyls, thus rendering them 
anionic, which would let them repulse the negatively charged DNA. In case the 
molecules do exert their action by targeting DNA, as is hypothesized, cytotoxic 
activity is expected to be abolished by the addition of the sulfonates. This theory 
has been confirmed by the data obtained from testing L-III and Ru-III on all the cell 
lines in the panel, as both the free ligand and the metal compound have mirrored 
the cytotoxic profile of the solvent DMSO (Figure 11 & 12), whereas the ligands L-I 
and L-II have exerted significant activity. This data allows us to stipulate that L-I and 
L-II could potentially act as DNA intercalators. It is important to note however, that 
conjugating two L-II ligands to a Ru metal (Ru-II) has led to significant activity being 
detected, whereas two L-I ligands conjugated to the metal (Ru-I) did not show any 
detectable activity. Therefore, according to our data, the addition of phenyl groups 
to phenanthroline could render the compounds derived from this molecule 
(diphenylphenanthroline) more active, by potentially exerting their action as DNA 
intercalators. Therefore, our data strongly traces any activity observed with one of 
our tested metal complexes to the coordination of a specific ligand, namely 
diphenylphenanthroline. The abolishment of activity observed with both L-III and 
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Ru-III despite their strong structural similarity to the highly potent L-II and Ru-II 
indicates that these compounds might act through DNA intercalation.  
Table 5: Binding constants for trisbidentate complexes of Ru(II) 
 
(From Clarke, 2003) 
It is important to note that previous data on trisbidentate complexes of Ru(II) 
(Ru core conjugated to three ligands) has been reviewed by Clarke (2003), in which 
compounds such as [Ru(bpy)3]2+ (Ru core conjugated to three bipyridine ligands), 
and [Ru(phen)3]2+ (Ru core conjugated to three phenanthroline ligands) (Table 5, 
structures of the tested ligands are drawn in Figure 29) were reported to not be 
likely intercalators. This data is in accordance with ours, since our tested 
compounds Ru-IV {[Ru(bpy)2Cl2]2+} and Ru-I {[Ru(phen)2Cl2]2+}, which are similar to 
[Ru(bpy)3]2+ and [Ru(phen)3]2+, respectively, (Table 5), have been shown to be 
inactive against our tested cell lines (Figures 11 & 12), and thus, suspected to not 
act as DNA intercalators. On the other hand, [Ru(bpy)2phen]2+ (Table 5), in which 
one phenanthroline and two bipyridine molecules are conjugated to the same Ru 
metal core, was reported to show no intercalating potential, whereas a similar 
compound, in which the single phenanthroline ligand is substituted with a 
diphenylphenanthroline ligand {[Ru(bpy)2dip]2+} was reported to show intercalative 
activity (Table 5). This data compares to the results that we have obtained with our 
compound Ru-II {[Ru(dip)2Cl2]2+}, which has two diphenylphenanthroline ligands 
conjugated to the Ru metal core, and has shown significant activity against the 
majority of our AML panel. This data strongly indicates that having at least one 
diphenylphenanthroline ligand conjugated to the Ru metal core is sufficient to 
confer detectable intercalative activity. Furthermore, as shown by Clarke (2003), 
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other combinations of ligands conjugated to the Ru metal core can also confer 
intercalative activity (Table 5). 
 
Figure 29: Structures of N-heteroaromatic ligands 
(From Clarke, 2003) 
In addition, data obtained with a ligand-free Ru metal compound (Ru-C) has 
shown that any observed cytotoxic activity cannot be due to the Ru metal itself 
(Figures 11 & 12), but requires the presence of specific ligands attached to it, as was 
shown with Ru-II, which is also in accordance with the data reviewed by Clarke 
(2003) (Table 5). 
Furthermore, the higher potency of L-I and L-II as compared to Ru-I and Ru-II, 
respectively, together with the observation that L-II starts to kill cells at the highest 
doses at significantly earlier time-points than Ru-II suggests that the free ligand 
probably involves a faster, simpler mechanism of action than that of the metal 
precursor. 
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In addition, as was also shown in Figures 18, 19 and 20, the general structure-
activity relationship observed with the free ligands and precursors is still respected 
in the final (tris) complexes in the dark, whereby the complexes carrying a majority 
of L-II ligands (and are hence non-anionic) exhibit potent and significant activity in 
the dark, whereas complexes that carry a majority of L-III ligands appear inactive 
due to their anionic character, and therefore their inability to intercalate into the 
poly-anionic DNA. 
4.2  Differences and Similarities in the Type of Cell Death and 
Cell Cycle Analyses in the Dark 
Our observation that both L-II and Ru-II exhibit apoptotic cell death contrasts 
with the lack of evidence of clear apoptosis in Ru-II3 and Ru-II2-III in the dark. 
Further investigation into this phenomenon is needed, in order to establish the type 
of cell death caused by these two final complexes in the dark and examine its 
implications. In addition, more data is needed to elucidate the different cell cycle 
responses detected as a result of treatment with the different compounds. 
4.3  Photo-Activation and an Activity Profile that does not obey 
the Structure-Activity Relationship 
The clear potentiation observed following light-activation in all final 
complexes, exceeding two orders of magnitude in the compounds inactive in the 
dark (Ru-II-III2 and Ru-III3) shows promising perspectives for development of 
photodynamic therapies with these two agents, since they abide by the general rule 
of being both stable and inactive in their pro-drug form in the dark. Physicochemical 
characterization by our collaborators has detected a release of reactive oxygen 
species (ROS) in all four complexes upon light-activation, this result however, still 
needs to be confirmed in later biological experiments. Further investigation of the 
effects observed upon light-activation in all four compounds is still required. 
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4.4  Conclusion 
In conclusion, we have tested different Ruthenium metal complexes, in which 
the metal is conjugated to phenanthroline- or bipyridine-derived ligands versus the 
corresponding free ligands against a panel of AML cell lines. We have detected 
significant activity in one of the Ru precursor complexes (Ru-II), which contains two 
diphenylphenanthroline ligands, whereas no effect was detected with the other 
precursors tested. In addition, testing the free ligands has shown significant activity 
of phenanthroline (L-I) as well as an even higher activity of diphenylphenanthroline 
(L-II), whereas the addition of sulfonate groups to diphenylphenanthroline (L-III) has 
abolished any activity, whether in the free ligand or in the metal complex, strongly 
suggesting that the suspected targeting of the DNA by intercalation is the 
mechanism by which phenanthroline-derivatives exert their action. On the other 
hand, neither bipyridine nor its precursor has shown any detectable activity. We 
have shown the observed activity to not be due to the Ru metal itself, but requiring 
the presence of specific ligands, namely diphenylphenanthroline, or other 
phenanthroline derivatives, as reviewed by Clarke (2003). Furthermore, our data 
clearly shows that the more hydrophobic phenanthroline-derivative 
diphenylphenanthroline (L-II) is highly toxic in comparison to phenanthroline itself, 
as well as to its Ru(II) precursor (Ru-II) and final tris compound (Ru-II3), strongly 
suggesting that there is a positive correlation between the ligand’s hydrophobicity 
and its intercalative potential. Differences were shown in the type of cell death and 
cell cycle analysis observed with the different complexes, suggesting that they 
might not all act through the same mechanism of action, even in the dark. Photo-
activation of all final complexes showed a marked potentiation reaching more than 
two orders of magnitude for the compounds inactive in the dark, suggesting an 
activity through a different mechanism of action, possibly the release of ROS, and 
leading to the possibility of developing successful photodynamic therapies with Ru-
II2-III and/or Ru-III3. Future work is still required to identify the full mechanisms 
underlying the observed effects of the compounds, possibly leading the way for 
future targeted photodynamic therapies against AML. 
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